Evidence map›Paper›PMID 41448580›Full record

ArticleACS synthetic biology2026

Systematic Evaluation of Vector Sequence Elements in Isogenic CHO Cells for Improved Antibody Production.

Marzia Rahimi, Anna Christina Adams, Lise Marie Grav, Lars K Nielsen, Jesús Lavado-García

Abstract read
In one paragraph

Article in ACS synthetic biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Marzia RahimiThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby 2800, Denmark.
Anna Christina AdamsThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby 2800, Denmark.
Lise Marie GravThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby 2800, Denmark.
Lars K NielsenThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby 2800, Denmark.
Jesús Lavado-GarcíaThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby 2800, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Monoclonal antibodies (mAbs) constitute a leading class of biotherapeutics, and meeting global demand requires manufacturing platforms that deliver rapid and reliable expression. Nevertheless, efficient and predictable production remains challenging because multiple vector elements can substantially influence productivity and product quality. In this study, we examined how sequence design features influence expression in a targeted-integration CHO system using six antibodies (A-F). We evaluated codon usage in the constant light (CL) and constant heavy (CH) regions with and without LALA/YTE Fc mutations, the type of signal peptide, codon optimization of the variable regions, and substitution of the kappa light chain with lambda. We found that changing codons of CL and CH to suboptimal codons reduced expression for all six antibodies, independent of LALA/YTE status. Replacing chain-specific signal peptides with a single identical peptide produced antibody-specific outcomes: productivity decreased for four antibodies (A, C, D, and E), increased for antibody B by ∼1.5-fold, and remained unchanged for antibody F. In addition, codon optimization of the variable regions generally enhanced productivity in an antibody-dependent manner, with improvements ranging from ∼2-fold to ∼18-fold. Finally, substituting kappa with lambda decreased productivity for three antibodies, suggesting a CHO cell preference for the kappa isotype. Collectively, these findings delineate practical sequence-engineering principles for CHO expression, prioritize codon usage in constant and variable domains, maintain chain-appropriate signal peptides, and account for kappa/lambda dependencies, thereby improving construct selection and accelerating development of high-yielding mAb producers.

Indexed as

Antibodies, MonoclonalGenetic VectorsAnimalsCHO CellsCodonCricetinaeCricetulusProtein EngineeringProtein Sorting SignalsAntibodies, MonoclonalCodonProtein Sorting Signalsantibody productivityCHO cellscodon optimizationmonoclonal antibody expressionsequence engineeringsignal peptides

Identifiers

PMID41448580
PMCPMC12814561

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.